A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with diff Erent anti-tumor necrosis factor therapies

A retrospective observational study

Shintaro Hirata, Wanying Li, Nadine Defranoux, Guy Cavet, Rebecca Bolce, Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives. To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. Methods. The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (Δ) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. Results. The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. Δ MBDA scores over 1 year correlated with Δ DAS28-ESR (r = 0.48) and Δ DAS28-CRP (r = 0.46). Linear relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were not signifi cantly diff erent between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: - 29) than moderate (– 21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. Conclusions. MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were consistent across the three TNF inhibitor groups.

Original languageEnglish
Pages (from-to)344-349
Number of pages6
JournalModern Rheumatology
Volume25
Issue number3
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Observational Studies
Rheumatoid Arthritis
Retrospective Studies
Tumor Necrosis Factor-alpha
Biomarkers
Therapeutics
Environmental Health
Occupational Health
Japan

Keywords

  • Biomarkers
  • Disease activity
  • Rheumatoid arthritis
  • TNF inhibitor

ASJC Scopus subject areas

  • Rheumatology

Cite this

A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with diff Erent anti-tumor necrosis factor therapies : A retrospective observational study. / Hirata, Shintaro; Li, Wanying; Defranoux, Nadine; Cavet, Guy; Bolce, Rebecca; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya.

In: Modern Rheumatology, Vol. 25, No. 3, 2015, p. 344-349.

Research output: Contribution to journalArticle

Hirata, Shintaro ; Li, Wanying ; Defranoux, Nadine ; Cavet, Guy ; Bolce, Rebecca ; Yamaoka, Kunihiro ; Saito, Kazuyoshi ; Tanaka, Yoshiya. / A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with diff Erent anti-tumor necrosis factor therapies : A retrospective observational study. In: Modern Rheumatology. 2015 ; Vol. 25, No. 3. pp. 344-349.
@article{4263f93b4eab4d5fa3a79da0c45c698e,
title = "A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with diff Erent anti-tumor necrosis factor therapies: A retrospective observational study",
abstract = "Objectives. To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. Methods. The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (Δ) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. Results. The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. Δ MBDA scores over 1 year correlated with Δ DAS28-ESR (r = 0.48) and Δ DAS28-CRP (r = 0.46). Linear relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were not signifi cantly diff erent between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: - 29) than moderate (– 21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. Conclusions. MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were consistent across the three TNF inhibitor groups.",
keywords = "Biomarkers, Disease activity, Rheumatoid arthritis, TNF inhibitor",
author = "Shintaro Hirata and Wanying Li and Nadine Defranoux and Guy Cavet and Rebecca Bolce and Kunihiro Yamaoka and Kazuyoshi Saito and Yoshiya Tanaka",
year = "2015",
doi = "10.3109/14397595.2014.958893",
language = "English",
volume = "25",
pages = "344--349",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with diff Erent anti-tumor necrosis factor therapies

T2 - A retrospective observational study

AU - Hirata, Shintaro

AU - Li, Wanying

AU - Defranoux, Nadine

AU - Cavet, Guy

AU - Bolce, Rebecca

AU - Yamaoka, Kunihiro

AU - Saito, Kazuyoshi

AU - Tanaka, Yoshiya

PY - 2015

Y1 - 2015

N2 - Objectives. To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. Methods. The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (Δ) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. Results. The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. Δ MBDA scores over 1 year correlated with Δ DAS28-ESR (r = 0.48) and Δ DAS28-CRP (r = 0.46). Linear relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were not signifi cantly diff erent between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: - 29) than moderate (– 21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. Conclusions. MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were consistent across the three TNF inhibitor groups.

AB - Objectives. To assess the ability of a multi-biomarker disease activity (MBDA) score to track clinical response in patients with rheumatoid arthritis (RA) treated with different TNF inhibitors. Methods. The study included 147 patients who had received adalimumab, etanercept, or infliximab for a year or more, during routine clinical care at the University Hospital of Occupational and Environmental Health, Japan. MBDA scores and clinical measures of disease activity were evaluated at baseline and, after 24 weeks (N = 84) and 52 weeks of treatment. Relationships between the changes (Δ) in MBDA score and changes in clinical measures or EULAR response categories were evaluated. Results. The median disease activity was 5.7 by DAS28-ESR and 64 by MBDA score at baseline, and decreased significantly with treatment. Δ MBDA scores over 1 year correlated with Δ DAS28-ESR (r = 0.48) and Δ DAS28-CRP (r = 0.46). Linear relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were not signifi cantly diff erent between TNF inhibitors. The MBDA scores declined significantly more in good responders (median change: - 29) than moderate (– 21), and more in moderate than in non-responders (+ 2), by the EULAR criteria. Conclusions. MBDA scores tracked disease activity and treatment response in patients with RA treated with three TNF inhibitors. The relationships between Δ MBDA scores and Δ DAS28-ESR or Δ DAS28-CRP were consistent across the three TNF inhibitor groups.

KW - Biomarkers

KW - Disease activity

KW - Rheumatoid arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84929472825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929472825&partnerID=8YFLogxK

U2 - 10.3109/14397595.2014.958893

DO - 10.3109/14397595.2014.958893

M3 - Article

VL - 25

SP - 344

EP - 349

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -